Private Advisor Group’s Theriva Biologics TOVX Stock Holding History

Private Advisor Group’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Hold	0	–	–	–	3257
2020 Q2	–	Hold	0	–	–	–	3915
2018 Q2	–	Sell	-1	Closed	-$3K	–	1447
2018 Q1	$3K	Buy	+1	New	+$3.8K	﹤0.01%	1148
2017 Q4	–	Sell	-2	Closed	-$14K	–	1400
2017 Q3	$14K	Hold	2	–	–	﹤0.01%	1455
2017 Q2	$8K	Hold	2	–	–	﹤0.01%	1373
2017 Q1	$9K	Hold	2	–	–	﹤0.01%	1403
2016 Q4	$19K	Sell	2 -1	-33%	-$10.3K	﹤0.01%	1257
2016 Q3	$44K	Buy	3 +2	+200%	+$29.9K	﹤0.01%	1095
2016 Q2	$18K	Hold	1	–	–	﹤0.01%	1105
2016 Q1	$24K	Buy	+1	New	+$15K	﹤0.01%	1013

Other funds holding TOVX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

Private Advisor Group's TOVX Position: Q3 2020 in Review

Private Advisor Group held its Theriva Biologics (TOVX) position steady in Q3 2020 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #3257.

Private Advisor Group first reported a position in TOVX in Q1 2016 and has held it in 8 quarters since. The position peaked at $44K in Q3 2016. 14 funds tracked by Wall St. Rank hold TOVX as of Q3 2020.

Private Advisor Group held 0 shares of Theriva Biologics worth $0 as of Q3 2020.
Private Advisor Group left its Theriva Biologics share count unchanged in Q3 2020.
Theriva Biologics made up ﹤0.01% of Private Advisor Group's portfolio in Q3 2020, its #3257 holding.
Private Advisor Group first reported a position in Theriva Biologics in Q1 2016 and has held it in 8 quarters since.
Private Advisor Group's Theriva Biologics position peaked at $44K in Q3 2016.
14 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.